Your browser is no longer supported. Please, upgrade your browser.
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own11.10% Shs Outstand25.43M Perf Week-18.12%
Market Cap526.15M Forward P/E- EPS next Y-1.73 Insider Trans0.00% Shs Float19.69M Perf Month-5.14%
Income-38.80M PEG- EPS next Q-0.53 Inst Own14.64% Short Float0.42% Perf Quarter-
Sales- P/S- EPS this Y-98.80% Inst Trans- Short Ratio0.26 Perf Half Y-
Book/sh-82.10 P/B- EPS next Y8.00% ROA- Target Price34.33 Perf Year-
Cash/sh1.04 P/C19.93 EPS next 5Y- ROE- 52W Range16.38 - 26.75 Perf YTD11.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-22.65% Beta-
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low26.31% ATR1.44
Employees25 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)38.80 Volatility10.09% 6.70%
OptionableNo Debt/Eq- EPS Q/Q-109.20% Profit Margin- Rel Volume0.33 Prev Close20.55
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume319.08K Price20.69
Recom1.30 SMA20-13.30% SMA50-5.50% SMA200-5.50% Volume105,898 Change0.68%
Sep-05-17 08:00AM  Kala Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference Business Wire
Aug-14-17 01:57PM  Kala Pharma Has 2 Material Milestones Upcoming In Q4 Benzinga +9.31%
Jul-25-17 04:05PM  Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters Option Business Wire
Jul-23-17 10:36AM  IPOs This Week: Real Estate Unicorn Redfin Leads Weeks IPOs 24/7 Wall St.
Jul-20-17 11:36AM  Kala Pharmaceuticals Joins NASDAQ, the Biotech IPOs Keep Coming
10:49AM  [$$] Kala Pharmaceuticals Prices IPO at Midpoint of Range The Wall Street Journal
08:06AM  Kala Pharmaceuticals prices IPO at $15 a share MarketWatch
08:00AM  Kala Pharmaceuticals Announces Pricing of Initial Public Offering Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.